GNLX
GNLX
NASDAQ · Biotechnology

Genelux Corp

$2.47
-0.01 (-0.40%)
As of Sep 28, 10:22 PM ET ·
Financial Highlights (FY 2026)
Revenue
8.9K
Net Income
-38,334,860
Gross Margin
—
Profit Margin
-401,812.5%
Rev Growth
-91.0%
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin — — 58.3% 58.3%
Operating Margin -415,175.0% -373,659.7% -22.4% -22.6%
Profit Margin -401,812.5% -381,721.9% -22.1% -17.2%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 8.9K 98.8K 62.40M 61.85M
Gross Profit — — 36.39M 36.07M
Operating Income -36,809,415 -369,325,234 -14,003,493 -13,961,219
Net Income -38,334,860 -384,630,702 -13,759,336 -10,609,098
Gross Margin — — 58.3% 58.3%
Operating Margin -415,175.0% -373,659.7% -22.4% -22.6%
Profit Margin -401,812.5% -381,721.9% -22.1% -17.2%
Rev Growth -91.0% -91.0% +12.2% +11.1%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 27.99M 31.26M
Total Equity — — 51.92M 51.92M
D/E Ratio — — 0.54 0.60
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -39,314,622 -416,375,595 -15,040,886 -15,866,697
Free Cash Flow — — -13,384,851 -9,996,517